- Home
- SLRC vs IMNM Comparison
SLRC vs IMNM Comparison
Compare SLRC & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRC
- IMNM
- Stock Information
- Founded
- SLRC 2007
- IMNM 2006
- Country
- SLRC United States
- IMNM United States
- Employees
- SLRC N/A
- IMNM N/A
- Industry
- SLRC Finance/Investors Services
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- SLRC Finance
- IMNM Health Care
- Exchange
- SLRC Nasdaq
- IMNM Nasdaq
- Market Cap
- SLRC 889.2M
- IMNM 945.8M
- IPO Year
- SLRC 2010
- IMNM 2020
- Fundamental
- Price
- SLRC $16.43
- IMNM $10.30
- Analyst Decision
- SLRC Hold
- IMNM Strong Buy
- Analyst Count
- SLRC 6
- IMNM 7
- Target Price
- SLRC $16.13
- IMNM $24.57
- AVG Volume (30 Days)
- SLRC 149.7K
- IMNM 629.1K
- Earning Date
- SLRC 08-05-2025
- IMNM 08-06-2025
- Dividend Yield
- SLRC 9.98%
- IMNM N/A
- EPS Growth
- SLRC N/A
- IMNM N/A
- EPS
- SLRC 1.63
- IMNM N/A
- Revenue
- SLRC $222,445,000.00
- IMNM $12,589,000.00
- Revenue This Year
- SLRC N/A
- IMNM N/A
- Revenue Next Year
- SLRC $0.22
- IMNM $154.73
- P/E Ratio
- SLRC $10.09
- IMNM N/A
- Revenue Growth
- SLRC N/A
- IMNM 16.74
- 52 Week Low
- SLRC $13.64
- IMNM $5.15
- 52 Week High
- SLRC $17.94
- IMNM $16.73
- Technical
- Relative Strength Index (RSI)
- SLRC 52.85
- IMNM 53.80
- Support Level
- SLRC $16.26
- IMNM $9.37
- Resistance Level
- SLRC $16.62
- IMNM $10.39
- Average True Range (ATR)
- SLRC 0.22
- IMNM 0.49
- MACD
- SLRC 0.02
- IMNM -0.06
- Stochastic Oscillator
- SLRC 75.70
- IMNM 52.81
About SLRC SLR Investment Corp.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.